Latest News of ENDP
J&J's Shockwave deal pays off as IVL catheter meets primary endpoint in trial
By Yahoo! Finance |
1 week ago
Johnson & Johnson's Javelin IVL catheter system by Shockwave Medical successfully met primary endpoints in a clinical trial for treating peripheral artery disease (PAD). The innovative system showed s...
LENZ Therapeutics Shares Climb After Presbyopia Trial Hits Endpoints
By MarketWatch |
3 weeks ago
LENZ Therapeutics' stock surged 13% in premarket trading after successful Phase 3 trial results for its presbyopia treatment in China. The study showed significant improvement in visual acuity, with p...
Alto Neuroscience Shares Plunge After ALTO-100 Study Misses Primary Endpoint
By MarketWatch |
3 weeks ago
Alto Neuroscience's stock hit record lows in after-hours trading after its ALTO-100 Phase 2 study failed to meet the primary goal. Shares dropped 63% to $5.36, hitting an intraday low of $7.91 in Augu...
-
Should You Start a Business With Your Friend? 4 Reasons to Try 'Friendpreneurship'
By Yahoo! Finance | 1 month agoConsider starting a business with a friend to reduce stress, establish trust, share workload, and align on vision and values. It can make entrepreneurship less lonely and offer various benefits. Explo...
-
MSD's Phase III trial of head and neck cancer treatment meets primary endpoint
By Yahoo! Finance | 1 month agoMerck & Co. reported positive results from the Phase III KEYNOTE-689 trial of KEYTRUDA for head and neck cancer treatment. The trial met its primary endpoint of event-free survival, with significant i...
-
Scholar Rock Holding's Spinal Muscular Atrophy Drug Apitegromab Meets Primary Study Endpoint
By MarketWatch | 1 month agoScholar Rock Holding's spinal muscular atrophy treatment met primary endpoints in phase 3 trial, showing significant motor function improvement. The drug received special designations and plans for re...
-
Daiichi Sankyo, Merck Phase 3 Lung-Cancer Study Meets Primary Endpoint
By MarketWatch | 2 months agoMerck & Co. and Daiichi Sankyo announced success in a late-stage lung cancer study with their drug candidate, patritumab deruxtecan....
-
Arrowhead to file NDA after pivotal rare disease trial meets all endpoints
By Yahoo! Finance | 2 months agoArrowhead Pharmaceuticals plans to submit a new drug application (NDA) to the FDA for its lead candidate, plozasiran, after successful results from the Phase III Palisade trial in patients with famili...
-
Jazz Pharmaceuticals's CBD Trial Misses Primary Endpoint
By MarketWatch | 2 months agoJazz Pharmaceuticals's trial of CBD for seizures in Japanese pediatric patients with certain diseases did not meet its primary goal. The company plans to collect more data and discuss a new drug appli...
-
BioNTech's cancer drug meets primary endpoint in Phase 2 trial
By Yahoo! Finance | 3 months agoBioNTech's cancer drug candidate BNT111 showed promising results in a Phase 2 trial for advanced melanoma patients, with a significant improvement in response rates when combined with a checkpoint inh...
-
Innovent's Phase III trial of type 2 diabetes treatment meets endpoints
By Yahoo! Finance | 3 months agoInnovent Biologics reports positive Phase III trial results of mazdutide for treating type 2 diabetes in Chinese patients....
-
EDAP TMS: Study of Endometriosis Treatment Missed Endpoint But Will Continue
By MarketWatch | 3 months agoEDAP TMS's Phase 3 study on robotic therapy for endometriosis didn't meet its acute pain reduction goal at three months but will continue. The company remains optimistic about the therapy's benefits b...
-
Roche's Phase II/III NSCLC treatment trial fails to meet primary endpoints
By Yahoo! Finance | 4 months agoRoche's Phase II/III SKYSCRAPER-06 trial of tiragolumab, Tecentriq, and chemotherapy for non-squamous NSCLC did not meet primary endpoints. The study will be stopped, with findings shared with health ...
-
More endpoints met in Insmed's Phase III brensocatib trial
By Yahoo! Finance | 4 months agoInsmed's Phase III ASPEN trial data reveals brensocatib's effectiveness in reducing lung function decline in bronchiectasis patients. Positive results support potential approval as a chronic treatment...
-
INmune Bio's unique Alzheimer's trial endpoint receives validation
By Yahoo! Finance | 4 months agoINmune Bio's AD02 trial for Alzheimer's disease, using TNF XPro with EMACC as the primary endpoint, shows positive results after FDA clinical hold. The trial's efficacy in assessing cognitive function...